- Market Capitalization, $K 1,742,673
- Shares Outstanding, K 65,098
- Annual Sales, $ 194,750 K
- Annual Income, $ -303,090 K
- 60-Month Beta 1.09
- Price/Sales 9.14
- Price/Cash Flow N/A
- Price/Book 13.01
|Period||Period Low||Period High||Performance|
| || |
-9.61 (-27.58%)since 04/25/22
| || |
-4.61 (-15.45%)since 02/25/22
| || |
-12.89 (-33.81%)since 05/25/21
The bears pounced on the company despite a first-quarter bottom-line beat.
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
GBT earnings call for the period ending March 31, 2022.
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth...
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate...
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1,...
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will...
|3rd Resistance Point||27.44|
|2nd Resistance Point||26.70|
|1st Resistance Point||25.97|
|1st Support Level||24.50|
|2nd Support Level||23.76|
|3rd Support Level||23.03|